Drugs similar to Flibanserin, bremelaontide to enhance libido loss due to antipsychoticsespecially in men (not necessarily)
Reading File
Searching PubMed
antipsychotic sexual dysfunction libido treatment
Searching the Web
drugs to treat antipsychotic-induced libido loss men flibanserin bremelanotide alternatives 2024 2025
Finding Sources
Reading Article
Reading Article
Searching PubMed
melanocortin bremelanotide libido men sexual desire
Reading File
Reading File
Searching PubMed
cabergoline aripiprazole antipsychotic sexual dysfunction treatment
Reading File
Reading Web Page
drugs treatment antipsychotic libido loss men flibanserin bremelanotide dopamine prolactin
Reading File
I have all the information needed for a thorough, well-structured answer. Here it is:
Drugs for Antipsychotic-Induced Libido Loss: Flibanserin, Bremelanotide, and Beyond
Why Antipsychotics Kill Libido
Antipsychotics suppress sexual desire through several overlapping mechanisms:
- Dopamine D2 blockade - directly reduces libido (dopamine normally enhances desire) and causes hyperprolactinaemia via tuberoinfundibular pathway blockade
- Hyperprolactinaemia - suppresses testosterone in men; explains ~40% of antipsychotic-related sexual dysfunction
- Alpha-1 blockade - causes erectile and ejaculatory problems in men
- Anticholinergic effects - impair arousal
- Sedation and weight gain - reduce desire indirectly
A 2023 JAMA Psychiatry meta-analysis (72 studies, 21,076 patients) found pooled sexual dysfunction prevalence of 56% overall, with loss of libido in 41% of men and erectile dysfunction in 44% of men [PMID: 37703012]. The worst offenders by prolactin-raising potential: risperidone > haloperidol > olanzapine > quetiapine > aripiprazole.
Flibanserin and Bremelanotide: Status in Men
Both are FDA-approved only for premenopausal women with HSDD, but their mechanisms are relevant:
| Drug | Mechanism | Status in Men |
|---|---|---|
| Flibanserin (Addyi) | 5-HT1A partial agonist + 5-HT2A antagonist + weak D4 antagonist; shifts neurotransmitter balance toward "pro-sexual" dopamine/norepinephrine dominance | Off-label; Phase 2 trial ongoing in men (recruiting 2025); 2024 J Sex Med abstracts report preliminary safety data in men |
| Bremelanotide (Vyleesi) | MC4R (melanocortin-4 receptor) agonist; activates central sexual circuits in the hypothalamus | Off-label for men; compounding pharmacies supply it widely; one 2024 J Sex Med abstract reports use in men with sexual dysfunction; not yet formally trialed for antipsychotic-induced HSDD |
Neither drug has published RCT data specifically for antipsychotic-induced libido loss.
Drugs with Similar or Complementary Mechanisms
1. Dopamine Agonists (Prolactin-Lowering) - Closest Mechanistic Match for Antipsychotic Context
These directly counter the dopamine-blocking, prolactin-raising effect of antipsychotics:
| Drug | Mechanism | Notes |
|---|---|---|
| Aripiprazole (adjunct) | D2 partial agonist - lowers prolactin while stabilizing the primary antipsychotic | Best-supported strategy; Maudsley: "may improve symptoms in combination with another antipsychotic"; brexpiprazole and cariprazine similarly favorable |
| Cabergoline | D2 agonist; directly lowers prolactin | Effective for hyperprolactinaemia-driven loss of libido; risk of exacerbating psychosis at high doses - use low doses (0.25-0.5 mg/week) |
| Bromocriptine | D2 agonist; older dopamine agonist | Similar to cabergoline; higher side-effect burden (nausea, vomiting); risk of psychosis worsening |
| Amantadine | Dopamine agonist/releaser | Specifically listed in Maudsley for "prolactin-induced reduction in desire and arousal"; risk of psychotic symptom exacerbation |
2. Melanocortin Pathway Agents (Same Class as Bremelanotide)
| Drug | Notes |
|---|---|
| PT-141 / Bremelanotide (compounded) | The same molecule; available off-label via compounding pharmacies for men; activates MC4R centrally; used in ED clinics |
| Setmelanotide (Imcivree) | MC4R agonist approved for genetic obesity; no libido data, but shares pathway |
| Investigational MC4R agonists | Several in pipeline; none yet approved for HSDD in either sex |
3. Serotonin Modulators (Same Class as Flibanserin)
Flibanserin's mechanism - boosting dopamine/NE while reducing serotonin tone - can be approximated by:
| Drug | Mechanism | Notes |
|---|---|---|
| Bupropion | NE + dopamine reuptake inhibitor; no serotonergic activity | Most evidence for antidepressant-induced sexual dysfunction; used off-label for antipsychotic-related libido loss; relatively well-tolerated |
| Buspirone | 5-HT1A partial agonist (same target as flibanserin's agonist component) | Listed in Maudsley for "SSRI-induced decreased libido"; also anxiolytic; less potent than flibanserin |
| Cyproheptadine | 5-HT2A antagonist (same target as flibanserin's antagonist component) | Useful for serotonin-excess sexual dysfunction; sedating; may blunt antidepressant effect |
| Pimavanserin | Inverse agonist at 5-HT2A/2C | Maudsley lists it specifically for "sexual dysfunction in depression with inadequate response to antidepressants; improvement in sexual function independent of effect on depression confirmed" - the most targeted serotonin option |
| Mirtazapine | NE agonist + 5-HT2/5-HT3 antagonist | May improve libido as an adjunct |
4. PDE5 Inhibitors - Targeted at Erectile Component
| Drug | Notes |
|---|---|
| Sildenafil, Tadalafil, Vardenafil | Maudsley: "effective even when prolactin-related"; do NOT directly improve libido/desire, only erectile function; useful if erectile dysfunction is contributing to avoidance |
| Alprostadil | Prostaglandin E1; intraurethral or intracavernosal; purely for erectile dysfunction |
5. Testosterone
| Approach | Notes |
|---|---|
| Testosterone supplementation | If hyperprolactinaemia has suppressed testosterone; address underlying prolactin first; TRT in men with documented low T due to antipsychotic use is a rational strategy |
6. Cholinergic Agents
| Drug | Notes |
|---|---|
| Bethanechol | For anticholinergic-induced arousal problems; Maudsley lists for "anticholinergic-induced arousal problems and anorgasmia" |
7. Adrenergic Agents
| Drug | Notes |
|---|---|
| Yohimbine | Alpha-2 adrenoceptor antagonist; Maudsley lists for "SSRI-induced sexual dysfunction, particularly erectile dysfunction, decreased libido and anorgasmia"; limited but positive data; can raise BP and cause anxiety |
Practical Decision Tree for Antipsychotic-Induced Low Libido in Men
Check prolactin level
|
Elevated?
/ \
YES NO
| |
Consider: Consider:
- Switch to - Bupropion adjunct
aripiprazole - Buspirone
- Add - Pimavanserin
aripiprazole - Testosterone
as adjunct (if low T)
- Cabergoline - PDE5i (for ED)
(low dose) - Bremelanotide
- Testosterone (off-label)
(if low T)
Summary Table
| Priority | Drug | Mechanism | Best For | Evidence Level |
|---|---|---|---|---|
| 1st line | Switch to/add aripiprazole | D2 partial agonist (lowers prolactin) | Prolactin-driven libido loss | High (RCTs) |
| 1st line | Bupropion | NE/DA reuptake inhibitor | General libido loss | Moderate (RCTs for SSRI-induced) |
| 2nd line | Cabergoline | D2 agonist (prolactin lowering) | Confirmed hyperprolactinaemia | Moderate |
| 2nd line | PDE5 inhibitors | Erectile mechanism | Erectile dysfunction + libido avoidance | High for ED |
| 2nd line | Testosterone | Androgen replacement | Low testosterone from prolactin suppression | Moderate |
| Adjunct | Buspirone | 5-HT1A agonist (like flibanserin) | Serotonin-component libido loss | Low-moderate |
| Adjunct | Pimavanserin | 5-HT2A inverse agonist | Serotonin-excess SD | Moderate (depression context) |
| Off-label | Bremelanotide | MC4R agonist | Desire + arousal (both sexes) | Low (no antipsychotic-specific RCTs) |
| Off-label | Flibanserin | 5-HT1A+2A + D4 | Low desire | Low (no antipsychotic-specific RCTs; men trial ongoing) |
| Off-label | Yohimbine | Alpha-2 antagonist | Libido + erectile | Low |
Key Caveats
- Flibanserin requires alcohol avoidance (hypotension/syncope risk) and is officially indicated only in women; its 5-HT1A agonism and 5-HT2A antagonism may be beneficial in antipsychotic-induced HSDD but no published trial yet specifically in this population.
- Bremelanotide (PT-141) raises blood pressure transiently and causes nausea; the melanocortin pathway operates upstream of dopamine/serotonin, so it may bypass the antipsychotic's blockade at the desire-generation level - making it theoretically attractive, but again no antipsychotic-specific RCT data exist.
- Dopamine agonists (cabergoline, bromocriptine, amantadine) carry a risk of destabilizing psychosis - they work against the mechanism of the antipsychotic - so must be used cautiously at low doses with close psychiatric monitoring.
- Switching the antipsychotic to a prolactin-sparing agent (aripiprazole, quetiapine, clozapine) is often the simplest and most effective intervention before adding any adjunctive drug.
Sources: Maudsley Prescribing Guidelines 15th ed. (pp. 220-227); Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Korchia et al., JAMA Psychiatry 2023 [PMID: 37703012]; Trinchieri et al., J Sex Med 2021 [PMID: 34247952].
This is a shared conversation. Sign in to Orris to start your own chat.